Natural course of localized prostate cancer. A personal view with a review of published papers

Anticancer Research

Volumn 17, Issue 3 A, 1997, Pages 1441-1448

  Hugosson, Jonas ^a   Aus, Gunnar ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Natural course; Prostate cancer; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; CANCER MORTALITY; CANCER PREVENTION; CANCER SURVIVAL; DIAGNOSTIC PROCEDURE; DISEASE COURSE; FOLLOW UP; HOSPITAL CARE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL RATE; SWEDEN; TIME FACTORS;

EID: 0031009983     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Boring CC, Squires TS, Tong T, Montgomery S: Cancer statistics 1994. Cancer J Clin 44: 7, 1994.
2. Causes of death 1993. Official Statistics of Sweden. National Central Bureau of Statistics, Stockholm 1995.
3. Gronberg H, Damber J-E, Jonsson H, Lenner P: Patient age as a prognostic factor in prostate cancer. J Urol 152: 892, 1994.
4. Aus G, Hugosson J, Norlen L: Need for hospital care and palliative treatment in prostate cancer treated with noncurative intent. J Urol 154: 466, 1995
5. Otnes B, Harvei S, Fossa SD: The burden of prostate cancer from diagnosis until death. Br J Urol 70: 587, 1995
6. Carlsson P, Hjertberg H, Jonsson B, Varenhorst E. The cost of prostatic cancer in a defined population. Scand J Urol Nephrol 23: 93-96, 1989.
7. Litwin MS, Hays RD, Fink A: Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 273: 129, 1995.
8. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations. Prostate 4: 473-485, 1983
9. Hanks GE, Radical prostatectomy or radiation therapy for early prostate cancer. Cancer 67: 2153-2160, 1988.
10. Pedersen K: Localized carcinoma of the prostate. Aspects on screening, staging and surgical treatment. Thesis Linkoping 1993.
11. Johansson JE, Andersson SE, Krusemo UB, Adami HO, Bergstrom R, Kraaz W. Natural history of localized prostatic cancer. Lancet 1989; ii 799-803.
12. Sakr WA, Haas GP, Cassin BF, Pontes JE. Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 150: 379, 1993.
13. Lundberg S, Berge T. Prostatic carcinoma. An autopsy study. Scand J Urol Nephrol 4: 9397, 1970.
14. Rich AR: On the frequency of occurrence of occult carcinoma of the prostate. J Urol 33: 215, 1935.
15. Miller GJ, Pfister SJ: Can we safely exclude patients with confined prostate cancer from treatment? In Recent advances in prostate cancer and BPH. Ed Fritz H. Schroder. Pp 231-234. The Parthenon Publishing Group. New York, London 1997.
16. Babaian, RJ, Troncoso, P, Steelhammer LC, LIoreta-Trull J and Ramirez EI: Tumour volume and prostate specific antigen: Implications for early detection and defining a window of curability. J Urol 154: 1808-1812, 1995.
17. Stamey TA, Kabalin JN, McNeal JE: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 141: 1076, 1989.
18. Labrie F, Candas B, Cusan L, Gomez J-L, Diamond P, Suburu R and Lemay M: Diagnosis of advanced or noncurable prostate cancer can be practically elimiated by prostatespecific antigen. Urology 47: 1-7, 1996.
19. Hugosson J: European randomized study for prostatic cancer: Results of PSA related screening in Goteborg. In: Recent advances in prostate cancer and BPH. Ed Fritz H. Schroder. Pp 179-184. Parthenon Publishing Group New York, London 1997.
20. Catalona WJ, Smith DS, Ralliff DL. Measurement of prostatespecific antigen in serum as a screening test for prostate cancer. N Engl J Med. 324: 1156-1161, 1991
21. Johansson J-E, Adami H-O, Andersson S-O. High 10-year-survival rate in patients with early untreated prostatic cancer. JAMA 267: 2191-2196, 1994.
22. Adolfsson J: Deferred treatment of low grade stage T3 prostate cancer without distant metastases. J Urol 149: 326, 1993.
23. Adolfsson J, Carstensen J, Lowhagen T. Deferred treatment in clinically localized prostatic carcinoma. Br J Urol 69: 183-187, 1992.
24. Johansson J-E, Holmberg L: The natural course of prostate cancer: Updated Orebro study. Scand J Urol Nephrol 29: 25 (suppl 174), 1995.
25. Johansson J-E, Holmberg L. 15-year survival in a cohort of prostate cancer patients. Scand J Urol Nephrol 29 (suppl 174): 26, 1995.
26. Gronberg H, Damber J-E. Damber L, Jonsson H: A population-based study of mortality from prostatic cancer in northern Sweden. Scand J Urol Nephrol 29 (suppl 174): 27, 1995.
27. Chodak GW, Thistedt RAt Gerber GS, Johansson J-E, Adolfsson J, Jones GW, Chisholm GD, Boaz Moskowitz, Livne PM, Warner J: Results of conservative management of clinically localized prostate cancer. N Engl J Med 330: 242, 1994
28. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J: Long-term survival among men with conservatively treated localized prostate cancer. JAMA 274: 626, 1995.
29. Aus G, Hugosson J, Norlen L: Long-term survival and mortality in prostate cancer treated with noncurative intent. J Urol 154: 460, 1995
30. Hugosson J, Aus G, Bergdahl C, Bergdahl S: Prostate cancer mortality inpatients surviving more than 10 years after diagnosis. J Urol 154: 2115, 1995
31. Goodman CM, Busuttil A, Chisholm GD: Age, size and grade of tumor predict prognosis in incidentally diagnosed carcinoma of the prostate. Br J Urol 62: 576, 1988.
32. Gronberg, Damber, Damber, Jonsson. Letter to the editor. J Urol. In print 1996.
33. Stenbeck M: Cancer survival in Sweden. Acta Oncol 34: 49 (suppl 4), 1995.
34. Norlen BJ: Survival and mortality in prostate cancer. A study based on the Swedish cancer registry. Acta Oncol 30: 141, 1991.
35. Abrahamsson, Adami, Taube, Zelen. Letter to the editor. J Urol: 96
36. Pettersson M. Comparison between inclusion criteria: estimation of long-term survival in prostate cancer. Departments of Statistics Goteborg University. Seminar Paper 1996: 13. ISSN 1100-6242, 1996.
37. Zincke H, Oesterling JE, Blute ML, Bergstrahl EJ, Myers RP, Barett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 152: 1850, 1994
38. Adolfsson J, Steineck G, Whitmore WF Jr: Recent results of management of palpable clinically localized prostate cancer. Cancer 72: 310, 1993.
39. Aus G, Pileblad E, Hugosson J: Impact of competing mortality on the cancer-related mortality in localized prostate cancer. Urology 46: 672, 1995
40. Lepor H, Kimball A.W, Walsh PC: Cause-specific actuarial survival analysis: a useful method for reporting survival data in men with clinically localized carcinoma of the prostate. J Urol 141: 82, 1989.
41. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457, 1958.
42. Hugosson J, Aus G, Norlen L. Surveillance is Not a Viable and Appropriate Treatment Option in the Management of Localized Prostate Cancer. Urol Clin North Am 23: 557-573, 1996.
43. Gann PH, Hennekens CH, Stampfer MJ: A prospective evaluation of plasma prostate specific antigen for detection of prostatic cancer. JAMA 273: 289, 1995.
44. Stenman CH: Serum concentrations of prostate specific antigen and its complex before diagnosis of prostate cancer. Lancet 344: L594, 1994.